Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | metampicillin | 6713928 | drug-path |
| ABC transporters | R-HSA-1369007 | map02010 | metampicillin | 6713928 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | nifenazone | 4487 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | nifenazone | 4487 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | nifenazone | 4487 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | nifenazone | 4487 | drug-path |
| Asthma | R-HSA-444620 | map05310 | nifenazone | 4487 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | nifenazone | 4487 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | nifenazone | 4487 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | nifenazone | 4487 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | nifenazone | 4487 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | nifenazone | 4487 | drug-path |
| Chronic myeloid leukemia | R-HSA-9680350 | map05220 | nifenazone | 4487 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | ethosuximide | 3291 | drug-path |
| ECM-receptor interaction | R-HSA-373711 | map04512 | ethosuximide | 3291 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | ethosuximide | 3291 | drug-path |
| Notch signaling pathway | R-HSA-157118 | map04330 | ethosuximide | 3291 | drug-path |
| RNA polymerase | R-HSA-73864 | map03020 | ethosuximide | 3291 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | chlorphenesin | 8569 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | chlorphenesin | 8569 | drug-path |